Brennan Kevin M., SVP of Finance and Accounting, sold Xilio Therapeutics ($XLO) shares once on the open market in the last year, totaling $1,174. His most recent sale occurred on January 2, 2026. These sales rank 11,537th among 11,678 insiders, far below the average of $8.6 million per seller and 6.4 transactions. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 1, 2026 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M | Common Stock | 5000 | $0.00 | 8,197.0000 | 144,106,869 | 156.40% | 0.00% |
| Jan. 1, 2026 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M | Restricted Stock Units | 5000 | $0.00 | 10,000.0000 | 144,106,869 | 33.33% | 0.00% |
| Dec. 31, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A | Stock Option (right to buy) | 95221 | $0.00 | 95,221.0000 | 144,106,869 | 9999.99% | 0.07% |
| Jan. 2, 2026 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | S | Common Stock | 1826 | $0.64 | 6,371.0000 | 144,106,869 | 22.28% | 0.00% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A | Stock Option (right to buy) | 55000 | $0.00 | 55,000.0000 | 144,106,869 | 9999.99% | 0.04% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A | Stock Option (right to buy) | 131700 | $0.00 | 131,700.0000 | 144,106,869 | 9999.99% | 0.09% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | D | Stock Option (right to buy) | 55000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.04% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | D | Stock Option (right to buy) | 25000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.02% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A | Stock Option (right to buy) | 25000 | $0.00 | 25,000.0000 | 144,106,869 | 9999.99% | 0.02% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | D | Stock Option (right to buy) | 20000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.01% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 144,106,869 | 9999.99% | 0.01% |
| Jan. 1, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M | Restricted Stock Units | 5000 | $0.00 | 15,000.0000 | 63,465,063 | 25.00% | 0.01% |
| Jan. 1, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 63,465,063 | 9999.99% | 0.09% |
| Jan. 2, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | S | Common stock | 1803 | $0.98 | 3,197.0000 | 63,465,063 | 36.06% | 0.00% |
| Jan. 1, 2025 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M | Common Stock | 5000 | $0.00 | 5,000.0000 | 63,465,063 | 9999.99% | 0.01% |
| Oct. 1, 2024 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A | Stock Option (right to buy) | 26000 | $0.00 | 26,000.0000 | 63,465,063 | 9999.99% | 0.04% |
| May 1, 2024 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 1, 2024 | Xilio Therapeutics, Inc. | $XLO | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A | Restricted Stock Units | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |